| Literature DB >> 35665440 |
Cunzhi Wang1,2, Pengrui Wang1,2, Wenbin Chen1,2, Yanyan Bai1,2.
Abstract
As a progressive chronic disease, the effective treatment for non-alcoholic fibre liver disease (NAFLD) has not yet been thoroughly explored at the moment. The widespread use of Gynostemma pentaphyllum (Thunb) for its anti-insulin resistance effect indicates that potential therapeutic value may be found in Thunb for NAFLD. Hence, this research aims to discover the latent mechanism of Thunb for NAFLD treatment. To achieve the goal of discovering the latent mechanism of Thunb for NAFLD treatment, molecular docking strategy integrated a network phamacology was adopted in the exploration. We acquire Thunb compounds with activeness from TCMSP database. We collect the putative targets of Thunb and NAFLD to generate the network. Key targets and mechanism are screened by PPI analysis, GO and KEGG pathway enrichment analyses. Molecular docking simulation is introduced into the study as assessment method. Through network analysis and virtual screening based on molecular docking, 2 targets (AKT 1 and GSK3B) are identified as key therapeutic targets with satisfying binding affinity. Main mechanism is believed to be the biological process and pathway related to insulin resistance according to the enrichment analyses outcomes. Particularly, the P13K-AKT signalling pathway is recognized as a key pathway of the mechanism. In conclusion, the study shows that Thunb could be a potential treatment against NAFLD and may suppress insulin resistance through the P13K-AKT signalling pathway. The result of the exploration provides a novel perspective for approaching experimental exploration.Entities:
Keywords: zzm321990Gynostemma pentaphyllumzzm321990; molecular docking; network pharmacology; non-alcoholic fibre liver disease
Mesh:
Substances:
Year: 2022 PMID: 35665440 PMCID: PMC9258700 DOI: 10.1111/jcmm.17410
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.295
Screening results of gynostemma pentaphyllum active constituents
| MolID | MolName | OB (%) | DL |
|---|---|---|---|
| MOL000338 | 3′‐methyleriodictyol | 51.61 | 0.27 |
| MOL000351 | Rhamnazin | 47.14 | 0.34 |
| MOL000359 | Sitosterol | 36.91 | 0.75 |
| MOL004350 | Ruvoside_qt | 36.12 | 0.76 |
| MOL004355 | Spinasterol | 42.98 | 0.76 |
| MOL005438 | Campesterol | 37.58 | 0.71 |
| MOL005440 | Isofucosterol | 43.78 | 0.76 |
| MOL007475 | Ginsenoside f2 | 36.43 | 0.25 |
| MOL000953 | CLR | 37.87 | 0.68 |
| MOL000098 | Quercetin | 46.43 | 0.28 |
| MOL009855 | (24S)‐Ethylcholesta‐5,22,25‐trans‐3beta‐ol | 46.91 | 0.76 |
| MOL009867 | 4α,14α‐dimethyl‐5α‐ergosta‐7,9(11),24(28)‐trien‐3β‐ol | 46.29 | 0.76 |
| MOL009877 | cucurbita‐5,24‐dienol | 44.02 | 0.74 |
| MOL009878 | Cyclobuxine | 84.48 | 0.7 |
| MOL009888 | Gypenoside XXXVI_qt | 37.85 | 0.78 |
| MOL009928 | Gypenoside LXXIV | 34.21 | 0.24 |
| MOL009929 | Gypenoside LXXIX | 37.75 | 0.25 |
| MOL009938 | Gypenoside XII | 36.43 | 0.25 |
| MOL009943 | Gypenoside XL | 30.89 | 0.21 |
| MOL009969 | Gypenoside XXXV_qt | 37.73 | 0.78 |
| MOL009971 | Gypenoside XXVII_qt | 30.21 | 0.74 |
| MOL009973 | Gypenoside XXVIII_qt | 32.08 | 0.74 |
| MOL009976 | Gypenoside XXXII | 34.24 | 0.25 |
| MOL009986 | Gypentonoside A_qt | 36.13 | 0.8 |
FIGURE 1(A) PPI network of NAFLD targets. (B) PPI network of NASH targets. The nodes range in size and colour from largeness to smallness, greenness to redness, according to descending sequence of extent
FIGURE 2Venn diagram and PPI network of compound‐NAFLD targets. (A) Venn diagram of intersecting targets of Thunb and NAFLD. (B) PPI network of compound‐NAFLD targets. (C) Venn diagram of intersecting targets of Thunb and NASH. (D) PPI network of compound‐NASH targets. Those nodes vary in their dimension and colour, which are displayed according to descending sequence of degree values from largeness to smallness and greenness to blueness
FIGURE 3Enrichment analyses of potential targets. (A) GO enrichment analyses of compound‐NAFLD (C) GO enrichment analyses of compound‐NASH. BP. Biological processes, CC; cellular component, MF; molecular functionalities. The top 10 terms of each part are shown. (B) KEGG pathway analyses of compound‐NAFLD. (D) KEGG pathway analyses of compound‐NASH. The bubbles vary in their dimension, which are displayed from large to small according to descending sequence of the quantity of the latent targets related to pathways
Outcomes of 13 hub genes and compounds of Thunb molecular docking
| Number | Hub genes | Uniprot ID | Compound | Docking affinity [kcal/mol] |
|---|---|---|---|---|
| 1 | AKT1 | P31749 | Quercetin | −6.36 |
| 2 | IL6 | P05231 | Quercetin | −4.42 |
| 3 | VEGFA | P15692 | Quercetin | −6.89 |
| 4 | JUN | P05412 | Quercetin | −3.39 |
| 5 | PTGS2 | P35354 | Quercetin | −6.95 |
| Rhamnazin | −6.73 | |||
| 3‐methyleriodictyol | −6.34 | |||
| 6 | MYC | P01106 | Quercetin | −3.23 |
| 7 | CXCL8 | P10145 | Quercetin | −7.57 |
| 8 | MMP9 | P14780 | Quercetin | −6.22 |
| 9 | CASP3 | P42574 | Quercetin | −5.88 |
| 10 | IL1B | P01584 | Quercetin | −6.52 |
| 11 | CCL2 | P13500 | Quercetin | −6.41 |
| 12 | INSR | P06213 | Quercetin | −6.85 |
| 13 | GSK3B | P49841 | Rhamnazin | −5.82 |
FIGURE 4P13K–AKT signalling pathway has a central function in anti‐NAFLD system of Thunb. The yellow nodes refer to overlapping targets of NAFLD and Thunb targets, the red nodes represent key targets, and the green nodes mean the other targets in P13K–AKT signalling pathway
FIGURE 5Molecular docking models of active compounds binding to potential targets. The 3 pairs of molecular docking simulation are revealed. Schematics (2D) displayed the interactive statuses amid compounds and residues surrounded. The yellow dashed lines mean hydrogen bonds and the interacted distances are presented beside to the bonds. Schematics (3D) reveal that molecular model of the compound is in the binding pocket of the protein. The compounds are presented as stick model with blue colour. The amino acid residues surrounding are displayed by surface